RESUMEN
PURPOSE: To assess whether health-related quality of life (HRQOL) improved through a postmastectomy care program focused on breast cancer-related lymphedema (BCRL) protection/awareness. METHODS: Postoperative breast cancer patients were enrolled prospectively (February-2018 to September-2019) at Nursing and Obstetrics Faculty, Durango, Mexico. Sociodemographic/clinical characteristics, arm measurements, and HRQOL evaluation with Functional Assessment Cancer Therapy-Breast Cancer were collected at baseline and after six follow-up assessments between six-to-twelve-month postmastectomy. Lymphedema was verified through circometry. Descriptive analysis and McNemar-Bowker test were used to evaluate paired differences in HRQOL. Subgroup analysis was conducted to assess sociodemographic/clinical characteristics of BCRL using Pearson's chi-squared or Fisher exact test along with odds ratios (OR) and 95% confidence intervals (CI). All tests were two-sided with P-values < 0.05 considered statistically significant. RESULTS: One-hundred-two patients developed BCRL (incidence 66.2%, n = 154). All dimensions of HRQOL improved after the postmastectomy care program (P < 0.05). The subgroup analysis indicated that elementary academic degree (OR = 2.40, 95%CI: 1.01-5.69), laborer (OR = 9.85, 95%CI: 3.30-29.3), and total mastectomy (OR = 4.23, 95%CI: 1.20-14.9) were more associated with BCRL (P < 0.05). Conversely, high school academic degree (OR = 0.46, 95%CI: 0.22-0.94), married status (OR = 0.42, 95%CI: 0.21-0.86), housewife (OR = 0.27, 95%CI: 0.12-0.61), professional occupation (OR = 0.10, 95%CI: 0.01-0.64), and having no comorbidities (OR = 0.31, 95%CI: 0.15-0.63) were less associated with BCRL (P < 0.05). CONCLUSION: Although HRQOL improved through the postmastectomy care program, our findings suggest that lower education, working as a laborer, and total mastectomy may be more associated with BCRL. Continuing research may uncover liabilities among BCRL patients within limited-resources settings.
Asunto(s)
Mastectomía , Calidad de Vida , Humanos , Femenino , Estudios Prospectivos , México , Persona de Mediana Edad , Mastectomía/efectos adversos , Adulto , Anciano , Linfedema del Cáncer de Mama/etiología , Linfedema del Cáncer de Mama/terapia , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/complicacionesRESUMEN
INTRODUCTION: Seroma is the most common early complication following surgical breast cancer treatment. Its development is associated with pain, scar complications, adjuvant therapy delays, the need for outpatient visits, and increased care costs. OBJECTIVE: Assess seroma incidence and risk factors in women undergoing mastectomies. METHOD: This study comprises a prospective cohort encompassing women aged 18 or over undergoing mastectomies as a breast cancer treatment. Patients underwent physiotherapy on the 1st, 7th, and 30th postoperative days for kinetic-functional, skin, and wound healing assessments and were attended to by nurses for surgical wound care, draining liquid on the 7th, 14th, and 21st postoperative days. Seroma was defined as the presence of local fluctuations requiring puncture, regardless of the punctured volume. RESULTS: A total of 249 women were evaluated, with a mean age of 57.5 (SD = 11.8). A total of 77.1% were classified as overweight or obese, 60.2% were hypertensive, 21.3% were diabetic, 66.7% underwent neoadjuvant chemotherapy and 62.7% underwent axillary lymphadenectomies. Seroma incidence was 71.1%, requiring, on average, two aspiration punctures until condition resolution. Overweight or obese women and those who underwent axillary lymphadenectomies exhibited 1.92- and 2.06-fold higher risk for seroma development (OR = 1.92; 95% CI 1.02-3.61; p = 0.042; and OR = 2.06; 95% CI 1.17-3.63; p = 0.012), respectively. CONCLUSION: Seroma incidence was very high. Being overweight or obese and undergoing axillary lymphadenectomy comprise independent seroma development risk factors. This study is part of a randomized clinical trial evaluating the effectiveness of applying compressive taping to prevent post-mastectomy seroma, which was approved by the Brazilian National Cancer Institute, Research Ethics Committee (2,774,824), and it is registered in the ClinicalTrials.gov (NCT04471142, on July 15, 2020).
Asunto(s)
Neoplasias de la Mama , Mastectomía , Seroma , Humanos , Femenino , Seroma/etiología , Seroma/epidemiología , Neoplasias de la Mama/cirugía , Persona de Mediana Edad , Factores de Riesgo , Estudios Prospectivos , Incidencia , Mastectomía/efectos adversos , Mastectomía/métodos , Anciano , Adulto , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Escisión del Ganglio Linfático/efectos adversos , Escisión del Ganglio Linfático/métodos , Estudios de CohortesRESUMEN
El dolor es un síntoma frecuente de presentación en los casos de cáncer pulmonar y es un dolor refractario debido a la multiplicidad de generadores de dolor. Las presentaciones pueden ser una invasión pleural, metastasis costales, invasión mixta o síndrome costo-pleural, tumor de Pancoast, y metástasis vertebral con o sin invasion paravertebral. Se han desarrollado terapias intervencionales mínimamente invasivas para tratar el dolor, que en etapas tempranas en pacientes con dolor no controlado mejoran su condición de salud, mejoran su rendimiento para enfrentar la enfermedad y su tratamiento, y evitan o retrasan la escalada de opioides con sus efectos adversos asociados. Se requiere estandarizar las técnicas, mejorar la calidad de los ensayos clínicos y desarrollar guías de práctica clínica en un trabajo conjunto con oncología.
Pain is a frequent presenting symptom in cases of lung cancer and it is a refractory pain due to the multiplicity of pain generators. Clinical presentations may be pleural invasion, rib metastasis, mixed invasion or costo-pleural syndrome, Pancoast tumor, and vertebral metastasis with or without paravertebral invasion. Minimally invasive interventional therapies have been developed to treat pain, which in early stages in patients with uncontrolled pain improve their health condition, improve their performance in coping with the disease and its treatment, and prevent or delay the escalation of opioids with their associated side effects. It is necessary to standardize the techniques, improve the quality of clinical trials and develop clinical practice guidelines in a joint effort with oncology.
Asunto(s)
Humanos , Dolor en el Pecho/terapia , Dolor en Cáncer/terapia , Neoplasias Pulmonares/complicaciones , Ondas de Radio/uso terapéutico , Toracotomía/efectos adversos , Neuropatías del Plexo Braquial/terapia , Desnervación , Mastectomía/efectos adversosRESUMEN
Objective: The purpose of this study was to compare postoperative pain between SF flap and serratus anterior muscle (SM) in direct-to-implant breast reconstruction. Methods: This is a prospective cohort study that included 53 women diagnosed with breast cancer who underwent mastectomy and one-stage implant-based breast reconstruction from January 2020 to March 2021. Twenty-nine patients (54.7%) had SF elevation, and 24 patients (45.3%) underwent SM elevation. We evaluated patient-reported early postoperative pain on the first day after surgery. Also, it was reported that all surgical complications in the first month and patient reported outcomes (PROs) were measured with the BRECON 23 questionnaire. Results: The serratus fascia group used implants with larger volumes, 407.6 ± 98.9 cc (p < 0.01). There was no significant difference between the fascial and muscular groups regarding the postoperative pain score reported by the patients (2 versus 3; p = 0.30). Also, there was no difference between the groups regarding early surgical complications and PROs after breast reconstruction. Conclusion: The use of SF seems to cause less morbidity, which makes the technique an alternative to be considered in breast reconstruction. Although there was no statistical difference in postoperative pain scores between the fascia and serratus muscle groups.
Asunto(s)
Neoplasias de la Mama , Mamoplastia , Mastectomía , Dolor Postoperatorio , Colgajos Quirúrgicos , Humanos , Femenino , Estudios Prospectivos , Mastectomía/efectos adversos , Persona de Mediana Edad , Neoplasias de la Mama/cirugía , Mamoplastia/métodos , Mamoplastia/efectos adversos , Adulto , Fascia/trasplante , Medición de Resultados Informados por el Paciente , Resultado del Tratamiento , Implantación de Mama/métodosRESUMEN
INTRODUCTION: Seroma is a frequent complication that can affect the final result of reconstructive and cosmetic surgeries. METHODOLOGY: This study evaluated the effectiveness of 5-Fluorouracil and 75% hypertonic glucose in preventing seroma in a mastectomy rat model, as well as cellular and vascular events in adjacent tissues. A left mastectomy with lymphadenectomy was performed in 60 Wistar-Albino female rats. Animals randomly allocated to the control group (Group I; n = 20) were sutured right after mastectomy. The intervention groups received 1.0 mL of 75% hypertonic glucose (Group II; n = 20) or 1.0 mL of 5-Fluorouracil (Group III; n = 20) at the surgical site before suturing. The assessment of the presence of seroma was performed in all animals at 24, 48, and 72 h and on the 7th and 12th postoperative day. After the 12th day, a tissue sample was taken from the surgical site and sent for histological analysis. The occurrence of seroma was assessed using GEE. A significance level of 5% was adopted. RESULTS: Differences in seroma formation over time were observed for both Control Group I (p=0.041) and Intervention Group II (p<0.001). In Intervention Group III, there was no difference in the percentage and volume of seroma across the assessment points (p=0.627). When both the Control and Intervention Group II were compared to Intervention Group III, we found a reduction in seroma formation in the last group. The reduction in the inflammatory process was more regular to Intervention Group III. CONCLUSION: In this animal model, 5-Fluorouracil was more effective in preventing seroma formation than 75% Hypertonic Glucose. No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Asunto(s)
Glucosa , Mastectomía , Ratas , Animales , Mastectomía/efectos adversos , Seroma/etiología , Seroma/prevención & control , Seroma/cirugía , Fluorouracilo , Ratas Wistar , Modelos AnimalesRESUMEN
BACKGROUND AND OBJECTIVES: Neoadjuvant chemotherapy (NCH) has demonstrated efficacy in downsizing tumors and facilitating less extensive surgery. However, immediate breast reconstruction (IBR) after NCH has raised concerns regarding higher complication rates. This study evaluates the impact of NCH on outcomes following IBR with a latissimus dorsi flap and implant (LDI) after mastectomy. METHODS: Cases from a prospective maintained database were reviewed, and patients classified according to whether or not they received NCH. Risk factors and major and minor complications in both groups were then analyzed. RESULTS: Among the 196 patients who underwent 198 IBR procedures, 38.4% received NCH and 66.1% did not. The overall complication rate was 46.7% in the non-NCH group and 53.3% in the NCH group (p = 0.650). The presence of comorbidities increased the likelihood of any complication (odds ratio [OR]: 3.46; 95% confidence interval [CI]: 1.38-8.66; p = 0.008) as well as major complications (OR: 3.35; 95% CI: 1.03-10.95; p = 0.045). Although patients in the NCH group experienced more major complications (10.5% vs. 4.9%; p = 0.134) and early loss of breast reconstruction (3.9% vs. 0.8%; p = 0.128), these findings were not statistically significant. CONCLUSION: This study found no statistically significant association between NCH and higher risk of complications or loss of IBR with LDI after mastectomy.
Asunto(s)
Neoplasias de la Mama , Mamoplastia , Músculos Superficiales de la Espalda , Humanos , Femenino , Mastectomía/efectos adversos , Mastectomía/métodos , Terapia Neoadyuvante/métodos , Resultado del Tratamiento , Estudios Prospectivos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/etiología , Mamoplastia/efectos adversos , Mamoplastia/métodos , Siliconas , Estudios RetrospectivosRESUMEN
BACKGROUND: the use of nipple-sparing mastectomy (NSM) in local advanced breast cancer after neoadjuvant chemotherapy (NQT) is increasing, despite few studies on the subject. The aim of this systematic review was to determine the safety of NSM after neoadjuvant chemotherapy. METHODS: for this systematic review we searched MEDLINE; Cochrane; Scientific Electronic Library Online (SciELO); Embase and Scopus. A literature search of all original studies including randomized controlled trials, cohort studies and case-control studies comparing women undergoing NSM after neoadjuvant chemotherapy for breast cancer was undertaken. Outcomes were locoregional recurrence (LRR), nipple recurrence and distant recurrence (DR). Data analysis was undertaken to explore the safety of NSM after NQT. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on PROSPERO, number CRD42021276778. FINDINGS: a total of 437 articles were identified. Four articles were included with 1466 patients all of which had a high to serious risk of overall bias. Local recurrence in the NSM after the NQT group ranged from zero to 9.8%. Nippleareolar complex (NAC) recurrence ranged from zero to 2.1%. The distant recurrence rate ranged from 6.5% to 16%. Due to the lack of pattern among the control groups, it was not possible to perform a meta-analysis. INTERPRETATION: this review provides information for decision making in performing NSM after NQT. Despite the low rates of local recurrence and patients should be counseled about limited oncological information.
Asunto(s)
Neoplasias de la Mama , Humanos , Femenino , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Mastectomía/efectos adversos , Terapia Neoadyuvante , Pezones/cirugía , Tratamientos Conservadores del Órgano/efectos adversos , Estudios Retrospectivos , Recurrencia Local de Neoplasia/epidemiologíaRESUMEN
BACKGROUND: Venous Thromboembolism (VTE) is an important cause of morbidity in cancer patients. Breast cancer patients undergoing surgical treatment are at an increased risk of VTE. The aim of this study was to determine the frequency of VTE in patients who underwent surgery for the treatment of breast cancer and to identify the related risk factors. METHODS: A historical cohort of patients at the São Paulo State Cancer Institute (ICESP) underwent surgery for breast cancer. The inclusion criteria covered patients with invasive breast cancer or ductal carcinoma in situ who had breast surgery anytime from January 2016 to December 2018. RESULTS: Of the 1672 patients included in the study, 15 had a confirmed diagnosis of VTE (0.9%), and 3 of these had deep vein thrombosis (0.2%), and 12, had pulmonary thromboembolism (0.7%). Clinical and tumoral characteristics did not differ between the groups. The incidence of VTE was higher in patients who had undergone skin-sparing mastectomy or nipple-sparing mastectomy (p = 0.032). Immediate reconstruction, particularly with abdominal-based flaps (4.7%), increased VTE events (p = 0.033). Median surgical time was higher in patients with VTE episodes (p = 0.027), and total hospital length of stay increased in days (6 days vs. 2 days, p = 0.001). Neoadjuvant chemotherapy and postoperative prophylaxis with Low Molecular Weight Heparin (LMWH) were associated with lower VTE rates (0.2% vs. 1.2%, p = 0.048 and 0.7% vs. 2.7%, p = 0.039; respectively) in these patients. CONCLUSIONS: The incidence of VTE events in breast cancer patients who underwent surgery was 0.9%. Immediate reconstruction (especially with abdominal-based flaps), skin-sparing/nipple-sparing mastectomies, and longer surgeries were associated with increased risk. The LMWH postoperative prophylaxis reduced this risk.
Asunto(s)
Neoplasias de la Mama , Embolia Pulmonar , Tromboembolia Venosa , Humanos , Femenino , Tromboembolia Venosa/epidemiología , Tromboembolia Venosa/etiología , Tromboembolia Venosa/prevención & control , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/tratamiento farmacológico , Heparina de Bajo-Peso-Molecular/efectos adversos , Incidencia , Complicaciones Posoperatorias/etiología , Mastectomía/efectos adversos , Brasil/epidemiología , Embolia Pulmonar/epidemiología , Embolia Pulmonar/etiología , Anticoagulantes/uso terapéutico , Factores de RiesgoRESUMEN
OBJECTIVES: Pectoserratus plane block (PSPB) leads to lower postoperative pain intensity. We examined whether PSPB could also reduce the incidence of post-mastectomy pain syndrome (PMPS) in women undergoing breast cancer surgery. METHODS: We performed an extension study of a randomized trial that compared PSPB versus control in women undergoing mastectomy. The primary outcome was any chronic pain at the surgical site or adjacent areas, defined as persistent/recurrent pain lasting ≥3 months. Secondary outcomes included neuropathic pain (score ≥4 in the Douleur Neuropathique 4 questionnaire), use of analgesic/anti-inflammatory drugs, pain intensity through the short-form McGill Pain Questionnaire, and type, frequency, and location of the pain. RESULTS: Of the 60 patients that completed the 24-hour follow-up (short-term trial), 53 (88%) completed the long-term follow-up (27 in the PSPB group and 26 in the placebo group). Six of 27 patients (22%) in the PSPB group and 17 of 26 patients (65%) in the placebo group reported any chronic pain (relative risk [RR], 0.34; 95% confidence interval [95% CI]=0.16-0.73, P =0.005). The risk of neuropathic pain was also lower in the PSPB group than in the placebo group (18.5% vs. 54%, respectively; RR, 0.34; 95% CI=0.14-0.82, P =0.02). There were no differences regarding all other pain-related outcomes considering the patients who developed PMPS. DISCUSSION: The results suggest that, in the long term, PSPB-treated participants were associated with a statistically significantly lower risk of PMPS than those who received standard general anesthesia. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03966326).
Asunto(s)
Neoplasias de la Mama , Dolor Crónico , Neuralgia , Humanos , Femenino , Dolor Crónico/prevención & control , Dolor Crónico/complicaciones , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/complicaciones , Mastectomía/efectos adversos , Estudios de Seguimiento , Neuralgia/tratamiento farmacológico , Dolor Postoperatorio/tratamiento farmacológico , Dolor Postoperatorio/prevención & control , Dolor Postoperatorio/complicacionesRESUMEN
BACKGROUND: Skin-sparing mastectomy (SSM) is a surgical technique that aims to maximize skin preservation, facilitate breast reconstruction, and improve cosmetic outcomes. Despite its use in clinical practice, the benefits and harms related to SSM are not well established. OBJECTIVES: To assess the effectiveness and safety of skin-sparing mastectomy for the treatment of breast cancer. SEARCH METHODS: We searched Cochrane Breast Cancer's Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 9 August 2019. SELECTION CRITERIA: Randomized controlled trials (RCTs), quasi-randomized or non-randomized studies (cohort and case-control) comparing SSM to conventional mastectomy for treating ductal carcinoma in situ (DCIS) or invasive breast cancer. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. The primary outcome was overall survival. Secondary outcomes were local recurrence free-survival, adverse events (including overall complications, breast reconstruction loss, skin necrosis, infection and hemorrhage), cosmetic results, and quality of life. We performed a descriptive analysis and meta-analysis of the data. MAIN RESULTS: We found no RCTs or quasi-RCTs. We included two prospective cohort studies and twelve retrospective cohort studies. These studies included 12,211 participants involving 12,283 surgeries (3183 SSM and 9100 conventional mastectomies). It was not possible to perform a meta-analysis for overall survival and local recurrence free-survival due to clinical heterogeneity across studies and a lack of data to calculate hazard ratios (HR). Based on one study, the evidence suggests that SSM may not reduce overall survival for participants with DCIS tumors (HR 0.41, 95% CI 0.17 to 1.02; P = 0.06; 399 participants; very low-certainty evidence) or for participants with invasive carcinoma (HR 0.81, 95% CI 0.48 to 1.38; P = 0.44; 907 participants; very low-certainty evidence). For local recurrence-free survival, meta-analysis was not possible, due to high risk of bias in nine of the ten studies that measured this outcome. Informal visual examination of effect sizes from nine studies suggested the size of the HR may be similar between groups. Based on one study that adjusted for confounders, SSM may not reduce local recurrence-free survival (HR 0.82, 95% CI 0.47 to 1.42; P = 0.48; 5690 participants; very low-certainty evidence). The effect of SSM on overall complications is unclear (RR 1.55, 95% CI 0.97 to 2.46; P = 0.07, I2 = 88%; 4 studies, 677 participants; very low-certainty evidence). Skin-sparing mastectomy may not reduce the risk of breast reconstruction loss (RR 1.79, 95% CI 0.31 to 10.35; P = 0.52; 3 studies, 475 participants; very low-certainty evidence), skin necrosis (RR 1.15, 95% CI 0.62 to 2.12; P = 0.22, I2 = 33%; 4 studies, 677 participants; very low-certainty evidence), local infection (RR 2.04, 95% CI 0.03 to 142.71; P = 0.74, I2 = 88%; 2 studies, 371 participants; very low-certainty evidence), nor hemorrhage (RR 1.23, 95% CI 0.47 to 3.27; P = 0.67, I2 = 0%; 4 studies, 677 participants; very low-certainty evidence). We downgraded the certainty of the evidence due to the risk of bias, imprecision, and inconsistency among the studies. There were no data available on the following outcomes: systemic surgical complications, local complications, explantation of implant/expander, hematoma, seroma, rehospitalization, skin necrosis with revisional surgery, and capsular contracture of the implant. It was not possible to perform a meta-analysis for cosmetic and quality of life outcomes due to a lack of data. One study performed an evaluation of aesthetic outcome after SSM: 77.7% of participants with immediate breast reconstruction had an overall aesthetic result of excellent or good versus 87% of participants with delayed breast reconstruction. AUTHORS' CONCLUSIONS: Based on very low-certainty evidence from observational studies, it was not possible to draw definitive conclusions on the effectiveness and safety of SSM for breast cancer treatment. The decision for this technique of breast surgery for treatment of DCIS or invasive breast cancer must be individualized and shared between the physician and the patient while considering the potential risks and benefits of available surgical options.
Asunto(s)
Neoplasias de la Mama , Carcinoma Intraductal no Infiltrante , Mamoplastia , Humanos , Femenino , Carcinoma Intraductal no Infiltrante/cirugía , Carcinoma Intraductal no Infiltrante/etiología , Neoplasias de la Mama/cirugía , Mastectomía/efectos adversos , Mastectomía/métodos , Mamoplastia/efectos adversos , NecrosisRESUMEN
Breast cancer is the second most common diagnosed type of cancer in women. Chronic neuropathic pain after mastectomy occurs frequently and is a serious health problem. In our previous single-center, prospective, randomized controlled clinical study, we demonstrated that the combination of serratus anterior plane block (SAM) and pectoral nerve block type I (PECS I) with general anesthesia reduced acute postoperative pain. The present report describes a prospective follow-up study of this published study to investigate the development of chronic neuropathic pain 12 months after mastectomy by comparing the use of general anesthesia alone and general anesthesia with SAM + PECS I. Additionally, the use of analgesic medication, quality of life, depressive symptoms, and possible correlations between plasma levels of interleukin (IL)-1 beta, IL-6, and IL-10 collected before and 24 h after surgery as predictors of pain and depression were evaluated. The results showed that the use of SAM + PECS I with general anesthesia reduced numbness, hypoesthesia to touch, the incidence of patients with chronic pain in other body regions and depressive symptoms, however, did not significantly reduce the incidence of chronic neuropathic pain after mastectomy. Additionally, there was no difference in the consumption of analgesic medication and quality of life. Furthermore, no correlation was observed between IL-1 beta, IL-6, and IL-10 levels and pain and depression. The combination of general anesthesia with SAM + PECS I reduced the occurrence of specific neuropathic pain descriptors and depressive symptoms. These results could promote the use of SAM + PECS I blocks for the prevention of specific neuropathic pain symptoms after mastectomy.Registration of clinical trial: The Research Ethics Board of the Hospital Sirio-Libanes/Brazil approved the study (CAAE 48721715.0.0000.5461). This study is registered at Registro Brasileiro de Ensaios Clinicos (ReBEC), and ClinicalTrials.gov, Identifier: NCT02647385.
Asunto(s)
Neoplasias de la Mama , Neuralgia , Nervios Torácicos , Femenino , Humanos , Mastectomía/efectos adversos , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/complicaciones , Estudios de Seguimiento , Interleucina-10 , Estudios Prospectivos , Calidad de Vida , Interleucina-6/uso terapéutico , Dolor Postoperatorio/tratamiento farmacológico , Neuralgia/complicaciones , MúsculosRESUMEN
OBJECTIVE: Breast cancer is the most common malignant neoplasm in women worldwide. Surgery has been traditional treatment and, generally, it´s mastectomy with lymphadenectomy, that can causes postoperative pain. Therefore, we seek to study regional anesthesic techniques that can minimize this effect, such as the interpectoral block (PECS). METHODS: randomized controlled study with 82 patients with breast cancer who underwent mastectomy with lymphadenectomy from January 2020 to October 2021 in oncology hospital. INTERVENTIONS: two randomized groups (control - exclusive general anesthesia and PECS group - received PECS block with levobupivacaine/ropivacaine and general anesthesia). We applied a questionnaire with Numeric Rating Scale for pain 24h after surgery. We used Shapiro-Wilk, Mann-Whitney and Chi-square tests, and analyzed the data in R version 4.0.0 (ReBEC). RESULTS: in the PECS group, 50% were pain-free 24h after surgery and in the control group it was 42.86%. The majority who presented pain classified it as mild pain (VAS from 1 to 3) - (42.50%) PECS group and (40.48%) control group (p=0.28). Only 17.50% consumed opioids in the PECS group, similar to the control group with 21.43%. (p=0.65). There was a low rate of complications such as PONV in both groups. In the subgroup analysis, there was no statistical difference between the groups that used levobupivacaine or ropivacaine regarding postoperative pain and opioid consumption. DISCUSSION: the studied group had a low rate of pain in the postoperative period and it influenced the statistical analysis. There wasn´t difference in postoperative pain in groups. CONCLUSION: was not possible to demonstrate better results with the association of the PECS block with total intravenous analgesia. Need further studies to assess the efficacy of the nerve block.
Asunto(s)
Neoplasias de la Mama , Bloqueo Nervioso , Nervios Torácicos , Femenino , Humanos , Analgésicos Opioides , Neoplasias de la Mama/cirugía , Levobupivacaína , Escisión del Ganglio Linfático/efectos adversos , Mastectomía/efectos adversos , Bloqueo Nervioso/efectos adversos , Dolor Postoperatorio/tratamiento farmacológico , Dolor Postoperatorio/prevención & control , Dolor Postoperatorio/etiología , RopivacaínaRESUMEN
OBJECTIVE: Nipple-sparing mastectomy (NSM) has been traditionally used in selected cases with tumor-to-nipple distance > 2 cm and negative frozen section of the base of the nipple. Recommending NSM in unselected populations remains controversial. The present study evaluated the oncological outcomes of patients submitted to NSM in an unselected population seen at a single center. METHODS: This retrospective cohort study included unselected patients with invasive carcinoma or ductal carcinoma in situ (DCIS) who underwent NSM in 2010 to 2020. The endpoints were locoregional recurrence, disease-free survival (DFS), and overall survival (OS), irrespective of tumor size or tumor-to-nipple distance. RESULTS: Seventy-six patients (mean age 46.1 years) (58 invasive carcinomas/18 DCIS) were included. The most invasive carcinomas were hormone-positive (60%) (HER2 overexpression: 24%; triple-negative: 16%), while 39% of DCIS were high-grade. Invasive carcinomas were T2 in 66% of cases, with axillary metastases in 38%. Surgical margins were all negative. All patients with invasive carcinoma received systemic treatment and 38% underwent radiotherapy. After a mean of 34.8 months, 3 patients with invasive carcinoma (5.1%) and 1 with DCIS (5.5%) had local recurrence. Two patients had distant metastasis and died during follow-up. The 5-year OS and DFS rates for invasive carcinoma were 98% and 83%, respectively. CONCLUSION: In unselected cases, the 5-year oncological outcomes following NSM were found to be acceptable and comparable to previous reports. Further studies are required.
OBJETIVO: A mastectomia poupadora do complexo areolo-mamilar (MPM) tem sido tradicionalmente utilizada em casos selecionados com distância tumor-mamilo > 2 cm e biópsia de congelação da base do mamilo negativa. Recomendar MPM em populações não selecionadas continua controverso. Este estudo avaliou os resultados oncológicos de pacientes submetidas à MPM em uma população não selecionada atendida em um único centro. MéTODOS: Coorte retrospectivo incluindo pacientes não selecionadas com carcinoma invasivo ou carcinoma ductal in situ (CDIS) submetidas à MPM entre 2010 e 2020. Os desfechos incluíram: recorrência locorregional, sobrevida livre de doença (SLD) e sobrevida global (SG), independentemente do tamanho do tumor ou da distância tumor-mamilo. RESULTADOS: Setenta e seis pacientes (média: 46,1 anos de idade) (58 carcinomas invasivos/18 CDIS) foram incluídas. A maioria dos carcinomas invasivos era hormônio-positivo (60%) (superexpressão de HER2: 24%; triplo-negativo: 16%), enquanto 39% dos CDIS eram de alto grau histológico. Os carcinomas invasivos foram T2 em 66% dos casos, com metástases axilares em 38%. As margens cirúrgicas foram todas negativas. Todas as pacientes com carcinoma invasivo receberam tratamento sistêmico e 38% receberam radioterapia. Após um período médio de 34,8 meses, 3 pacientes com carcinoma invasivo (5,1%) e 1 com CDIS (5,5%) apresentaram recidiva local. Durante o acompanhamento, duas pacientes tiveram metástase à distância e vieram a óbito. As taxas de SG e SLD aos 5 anos para carcinoma invasivo foram de 98% e 83%, respectivamente. CONCLUSãO: Em casos não selecionados, os resultados oncológicos de 5 anos após MPM foram considerados aceitáveis e comparáveis a resultados anteriores. Estudos adicionais são necessários.
Asunto(s)
Neoplasias de la Mama , Carcinoma Intraductal no Infiltrante , Humanos , Persona de Mediana Edad , Femenino , Mastectomía/efectos adversos , Carcinoma Intraductal no Infiltrante/cirugía , Carcinoma Intraductal no Infiltrante/patología , Estudios Retrospectivos , Pezones/cirugía , Neoplasias de la Mama/patología , Recurrencia Local de Neoplasia/patologíaRESUMEN
Introducción: La mastectomía es una transformación dolorosa, con diversas repercusiones emocionales. La mujer que se enfrenta a este proceso a consecuencia del cáncer, se encuentra en una posición difícil, con pocas opciones, al considerar las posibilidades de continuar con su existencia y los cambios que esto implica. Objetivo: Conocer los cambios de estilo de vida que experimentan las mujeres con cáncer de mama después de la mastectomía. Métodos: Estudio cualitativo con diseño interpretativo, realizado en la Unidad de Oncología del Hospital Regional de Lambayeque, Chiclayo, Perú, de enero a junio de 2021. Por muestreo no probabilístico, fueron seleccionadas seis mujeres mastectomizadas, mayores de 18 años, con seguimiento en consulta mayor de un año y un familiar conviviente mayor de 18 años. Los datos se obtuvieron mediante entrevista semiestructurada y fueron analizados según el modelo de adaptación de Callista Roy. Resultados: La información recogida se categorizó, en correspondencia a cada elemento del modelo de adaptación de Callista Roy, en: necesidad fisiológica, cambios en la alimentación, dominio de rol, cambios en el rol de madre y esposa, y en interdependencia: las relaciones con los que la rodean (amigos, familia) y el aspecto laboral-profesional. Se destacaron cambios drásticos en la selección de alimentos, aislamiento, reducción de actividades; efecto en la carga laboral; importancia del apoyo familiar. Conclusión: El cáncer y la mastectomía exigen adaptaciones en la paciente y la familia. Sin embargo, ocurren transformaciones afectivas, que mueven sentimientos, valoración, admiración y acercamiento, que refuerzan los vínculos de pareja, familiares y de amigos, tan necesarios para lidiar con el proceso(AU)
Introduction: Mastectomy is a painful transformation, with diverse emotional repercussions. The woman who faces this process as a consequence of cancer finds herself in a difficult position, with few options, when considering the possibilities of continuing with her existence and the changes this implies. Objective: To know the lifestyle changes experienced by women with breast cancer after mastectomy. Methods: Qualitative study with interpretative design, conducted in the Oncology Unit of the Regional Hospital of Lambayeque, Chiclayo, Peru, from January to June 2021. By non-probabilistic sampling, six mastectomized women, older than 18 years, with a follow-up in consultation of more than one year and a cohabiting relative older than 18 years were selected. The data were obtained by semi-structured interview and were analyzed according to Callista Roy's adaptation model. Results: The information collected was categorized, according to each element of Callista Roy's adaptation model, as follows: physiological need, changes in diet, role dominance, changes in the role of mother and wife, and interdependence: relationships with those around her (friends, family) and the work-professional aspect. Drastic changes in food selection, isolation, reduction of activities; effect on workload; importance of family support were highlighted. Conclusion: Cancer and mastectomy require adaptations in the patient and family. However, emotional transformations occur, which move feelings, appreciation, admiration and closeness, which reinforce the couple, family and friends bonds, so necessary to deal with the process(AU)
Asunto(s)
Humanos , Femenino , Adulto , Neoplasias de la Mama/etiología , Mastectomía/efectos adversos , Relaciones FamiliaresRESUMEN
Abstract Background Breast cancer surgery is associated with considerable acute post-surgical pain and restricted mobility. Various regional and neuraxial anesthesia techniques have been used to alleviate post-mastectomy pain. Ultrasound-guided serratus anterior plane block (SAPB) has been considered a simple and safe technique. This randomized control study was performed to compare the efficacy of SAPB with the thoracic paravertebral block (TPVB) for postoperative analgesia after breast cancer surgery. Methods A total of 40 adult ASA physical status I - II female patients undergoing radical mastectomy were randomly allocated into two groups to receive either ultrasound-guided TPVB or SAPB with 0.4 mL.kg-1 0.5% ropivacaine, 30 min before surgery. All patients received standardized general anesthesia for surgery. Injection diclofenac and tramadol were used for postoperative rescue analgesia. The time to first rescue analgesia, total analgesic consumption in the first 24 hours, postoperative pain scores, and any adverse effects were recorded. Results The time to first rescue analgesia was significantly longer in the SAPB group (255.3 ± 47.8 min) as compared with the TPVB group (146.8 ± 30.4 min) (p< 0.001). Total diclofenac consumption in 24 hours was also less in the SAPB group (138.8 ± 44.0 mg vs 210.0 ± 39.2 mg in SAPB and TPVB group respectively, p< 0.001). Postoperative pain scores were significantly lower in the SAPB group as compared with TPVB group (p< 0.05). The incidence of PONV was also less in the SAPB group (p= 0.028). No block-related adverse effects were reported. Conclusion We found that the serratus anterior plane block was more effective than the thoracic paravertebral block for postoperative analgesia after breast cancer surgery.
Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Neoplasias de la Mama/cirugía , Analgesia , Dolor Postoperatorio/etiología , Dolor Postoperatorio/prevención & control , Dolor Postoperatorio/tratamiento farmacológico , Diclofenaco , Ultrasonografía Intervencional/métodos , Mastectomía/efectos adversosRESUMEN
INTRODUCTION: Lymphoedema associated with breast cancer is caused by an interruption of the lymphatic system, together with factors such as total mastectomy, axillary dissection, positive lymph nodes, radiotherapy, use of taxanes and obesity. Physiotherapy treatment consists of complex decongestive therapy, manual lymphatic drainage and exercises, among other interventions. Currently, there are several systematic review and randomised controlled trials that evaluate the efficacy of these interventions. However, at present, there are no studies that compare the effectiveness of all these physical therapy interventions. The purpose of this study is to determine which physical therapy treatment is most effective in reducing breast cancer-related lymphoedema, improving quality of life and reducing pain. METHODS AND ANALYSIS: MEDLINE, PEDro, CINAHL, EMBASE, LILACS and Cochrane Central Register of Controlled Trials will be searched for reports of randomised controlled trials published from database inception to June 2022. We will only include studies that are written in English, Spanish and Portuguese. We will also search grey literature, preprint servers and clinical trial registries. The primary outcomes are reduction of secondary lymphoedema associated with breast cancer, improvements in quality of life and pain reduction. The risk of bias of individual studies will be evaluated using the Cochrane Risk of Bias 2.0 Tool. A network meta-analysis will be performed using a random-effects model. First, pairs will be directly meta-analysed and indirect comparisons will be made between the different physical therapy treatments. The GRADE system will be used to assess the overall quality of the body of evidence associated with the main results. ETHICS AND DISSEMINATION: This protocol does not require approval from an ethics committee. The results will be disseminated via peer-reviewed publications. PROSPERO REGISTRATION NUMBER: CDR42022323541.
Asunto(s)
Neoplasias de la Mama , Linfedema , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/terapia , Enfermedad Crónica , Femenino , Humanos , Linfedema/cirugía , Linfedema/terapia , Mastectomía/efectos adversos , Metaanálisis como Asunto , Metaanálisis en Red , Dolor/complicaciones , Modalidades de Fisioterapia , Calidad de Vida , Revisiones Sistemáticas como Asunto , TaxoidesRESUMEN
Breast cancer-related lymphedema following axillary lymph node dissection (ALND) has been documented in 6%-55% of patients, mostly occurring within the next 3 years after radiation or surgery. We present a case of a 53-year-old patient with hormone positive, stage IB, left breast invasive ductal carcinoma treated with immediate lymphatic and microvascular breast reconstruction (MBR) using vascularized lymph node transfer (VLNT) for lymphedema prevention. A deep inferior epigastric perforator (DIEP) flap (18.3 × 11.2-cm) and simultaneous prophylactic gastroepiploic-VLNT (7 × 3-cm), orthotopically inset in the axilla, were used for reconstruction following mastectomy and radical ALND. The procedure was uneventful. The patient did not display increased postoperative arm circumferences. ICG lymphography did not show any changes at 2- and 3-years after surgery. Preventive lymphatic reconstruction with GE-VLNT and immediate MBR using the DIEP flap offers a new possibility for the primary prevention of lymphedema and simultaneous immediate autologous breast reconstruction without the risk of iatrogenic lymphedema. Further studies will be directed to unveil the external validity of these findings and the risk reduction rate of this approach.
Asunto(s)
Neoplasias de la Mama , Linfedema , Mamoplastia , Colgajo Perforante , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/cirugía , Femenino , Humanos , Ganglios Linfáticos/irrigación sanguínea , Linfedema/etiología , Linfedema/prevención & control , Linfedema/cirugía , Mamoplastia/efectos adversos , Mamoplastia/métodos , Mastectomía/efectos adversos , Persona de Mediana Edad , Colgajo Perforante/irrigación sanguíneaRESUMEN
The purpose of this chapter is to provide an account of the value granted to the oncologic medical tattoo by those women who have just finished their surgical and plastic breast reconstruction process following a mastectomy. To this end, we conducted in-depth interviews with the beneficiaries of the Aesthetical, Paramedical and Oncologic Micro-Pigmentation Foundation's (FEMPO) free program. Medical tattoos are positively evaluated in connection with post-breast cancer physical reconstruction; they are granted a high value due to the aesthetic effect and the simplicity of the intervention, both in the reconstruction of the areola-nipple complex and the reduction of scars and adverse effects from the adjuvant treatment on hair and eyebrows. Additionally, psychical meanings are granted that add value to the process; it is considered to be the end of a painful process, the recovery of a part of the body that had been lost, and the return to a healthy state. The above is seen as a landmark full of psychological and emotional reparation meanings. Finally, the empathic and close relationship with the team is also positively evaluated, as it helps women feel confident, promoting a caring environment beyond aesthetic considerations.
Asunto(s)
Neoplasias de la Mama , Mamoplastia , Tatuaje , Femenino , Humanos , Neoplasias de la Mama/cirugía , Mastectomía/efectos adversos , Mamoplastia/efectos adversos , Pezones/cirugíaRESUMEN
BACKGROUND: Breast cancer surgery is associated with considerable acute post-surgical pain and restricted mobility. Various regional and neuraxial anesthesia techniques have been used to alleviate post-mastectomy pain. Ultrasound-guided serratus anterior plane block (SAPB) has been considered a simple and safe technique. This randomized control study was performed to compare the efficacy of SAPB with the thoracic paravertebral block (TPVB) for postoperative analgesia after breast cancer surgery. METHODS: A total of 40 adult ASA physical status I - II female patients undergoing radical mastectomy were randomly allocated into two groups to receive either ultrasound-guided TPVB or SAPB with 0.4â¯mL.kg-1 0.5% ropivacaine, 30â¯min before surgery. All patients received standardized general anesthesia for surgery. Injection diclofenac and tramadol were used for postoperative rescue analgesia. The time to first rescue analgesia, total analgesic consumption in the first 24â¯hours, postoperative pain scores, and any adverse effects were recorded. RESULTS: The time to first rescue analgesia was significantly longer in the SAPB group (255.3⯱â¯47.8â¯min) as compared with the TPVB group (146.8⯱â¯30.4â¯min) (pâ¯<â¯0.001). Total diclofenac consumption in 24 hours was also less in the SAPB group (138.8 ± 44.0 mg vs 210.0 ± 39.2 mg in SAPB and TPVB group respectively, pâ¯<â¯0.001). Postoperative pain scores were significantly lower in the SAPB group as compared with TPVB group (pâ¯<â¯0.05). The incidence of PONV was also less in the SAPB group (pâ¯=â¯0.028). No block-related adverse effects were reported. CONCLUSION: We found that the serratus anterior plane block was more effective than the thoracic paravertebral block for postoperative analgesia after breast cancer surgery.